@article{e37bc60b197d416cabf99416e4ad84b5,
title = "How do we improve the utility of fractional flow reserve - For precise diagnosis of myocardial ischemia",
author = "Hideki Ishii and Toyoaki Murohara",
note = "Funding Information: H. Ishii received lecture fees from Astellas Pharma Inc., Astrazeneca Inc., Bayer Pharmaceutical Co., Ltd., Bristol-Myers Squibb Inc., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Pharma Inc., and MSD K.K. T. Murohara received lecture fees from Bayer Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi-aventis K.K., and Takeda Pharmaceutical Co., Ltd. T. Murohara received unrestricted research grant for Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-aventis K.K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.",
year = "2019",
doi = "10.1253/circj.CJ-19-0730",
language = "English",
volume = "83",
pages = "1986--1987",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "10",
}